Drug delivery carrier and anti-tumor application thereof

Abstract

The invention relates to a drug delivery carrier and an anti-tumor application thereof. Specifically, the invention provides a delivery carrier, which is characterized in that the delivery carrier comprises nanoparticles and albumin, and the nano material of the nanoparticles comprises PEG-PCL-PEI; and the albumin is used for modifying the nanoparticles. The delivery carrier disclosed by the invention can be used for loading a drug to form a drug compound of drug-loaded nanoparticles, and the drug-loaded nanoparticles can effectively permeate into a tumor part from a tumor vessel through endocytosis and exocytosis transport effects, and can be effectively absorbed and taken by tumor cells; the lysosome escape capability and the lysosome degradation avoiding capability are realized, the advantages of excellent long-time blood clearance half-life period, high system biological safety and the like are realized, and the anti-tumor effect of the medicine can be obviously improved.

Description

technical field [0001] The invention relates to the field of medicines, in particular to a medicine delivery carrier and its anti-tumor application. Background technique [0002] Tumors are a serious threat to life and health, and the research on anti-tumor drugs and their delivery vehicles has become a research hotspot today. [0003] An important reason for the poor anti-tumor effect of existing anti-cancer drugs is that the anti-cancer drugs have poor tumor blood vessel permeability and are difficult to be absorbed and taken up by tumor cells, which greatly limits the therapeutic effect of anti-cancer drugs. Especially for tumors with low vascular permeability, because the tumor vascular endothelial cells are well-organized and tightly packed, and the gap between vascular endothelial cells is small, even when the drug is delivered to the blood vessels of these tumors, because the drug is well-organized and tightly packed tumor vascular endothelium It is difficult to effe...

AI Technical Summary

Problems solved by technology

[0003] An important reason for the poor anti-tumor effect of existing anti-cancer drugs is that the anti-cancer drugs have poor tumor blood vessel permeability and are difficult to be absorbed and taken up by tumor cells, etc., which greatly limits the therapeutic effect of anti-cancer drugs

Especially for tumors with low vascular permeability, because the tumor vascular endothelial cells are well-organized and tightly packed, and the gap between vascular endothelial cells is small, even when the drug is delivered to the blood vessels of these tumors, because the drug is well-organized and tightly packed tumor vascular endothelium It is difficult to effectively penetrate the gap between vascular endothelial cells and reach the microenvironment of the tumor site. Therefore, when the existing antitumor drugs are used to treat tumors with low vascular permeability, they pass through the traditional tumor permeability and retention effects ( Enhanced Permeability and Retention, EPR effect) cannot effectively penetrate from the gap of tumor blood vessels to the tumor site, and thus cannot effectively exert the anti-tumor effect

In addition, for tumors, even if anti-tumor drugs penetrate into the tumor site from tumor blood vessels, the absorption and uptake of anti-tumor drugs by tumor cells will reduce the anti-tumor effect, so that the anti-tumor effect of the drug cannot be effectively exerted

In addition, anti-tumor drugs are easy to accumulate in lysosomes, and various enzymes in lysosomes degrade the drugs, reducing the stability of the drugs in tumor cells, thereby reducing the anti-tumor effect of the drugs

[0004] Although nanocarriers provide many alternative strategies for chemotherapeutic drugs, however, existing drug-loaded nanoparticles have many disadvantages, for example, after intravenous administration, they are prone to sudden release and short blood circulation time, resulting in greater systemic toxicity. Side effects, low biological safety, such as prone to hemolysis and inability to effectively accumulate in the tumor site, in addition, the existing drug-loaded nanoparticles can not effectively penetrate into the tumor site from the tumor vascular space through the EPR effect (especially for tumors with low vascular permeability ) and the tumor has a poor ability to uptake the drug-loaded nanoparticles, so it cannot effectively achieve the anti-tumor effect

In addition, the existing drug-loaded nanoparticles are also easy to aggregate in lysosomes, and various enzymes in lysosomes degrade the nanoparticles and their loaded drugs, reducing the stability of drugs in tumor cells, thereby reducing the Anti-tumor effect

Images